A non-surgical method for subretinal delivery by trans-scleral microneedle injection

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Amir Hejri, Micah A. Chrenek, Nolan T. Goehring, Isabella I. Bowland, Richard Noel, Jiong Yan, John M. Nickerson, Mark R. Prausnitz
{"title":"A non-surgical method for subretinal delivery by trans-scleral microneedle injection","authors":"Amir Hejri,&nbsp;Micah A. Chrenek,&nbsp;Nolan T. Goehring,&nbsp;Isabella I. Bowland,&nbsp;Richard Noel,&nbsp;Jiong Yan,&nbsp;John M. Nickerson,&nbsp;Mark R. Prausnitz","doi":"10.1002/btm2.10755","DOIUrl":null,"url":null,"abstract":"<p>Novel therapeutics have emerged for treating neurodegenerative eye diseases but are limited by non-optimal methods of ocular administration. Subretinal injection is the preferred method of delivery for retinal gene and stem-cell therapies, but its invasive and complex surgical procedure is a major limiting factor in clinical investigations and practice. Here, we engineered a novel trans-scleral injection technique to safely administer to the subretinal space in a simple, non-surgical, and minimally invasive procedure. Subretinal injection using this technique in rodents and rabbits took &lt;1 min per injection and did not require a surgical microscope. Extensive safety examinations in rats showed that the injection technique reliably administered into the subretinal space with no incidence of retinal perforation, little or no choroidal bleeding, and no evidence of retinal toxicity. We further found that repeated subretinal injection in the same eye, in rats, was well tolerated. The developed technique may enable non-surgical subretinal injection without vitrectomy, potentially increasing safety, efficacy, and access to ocular therapies.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"10 3","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.10755","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/btm2.10755","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Novel therapeutics have emerged for treating neurodegenerative eye diseases but are limited by non-optimal methods of ocular administration. Subretinal injection is the preferred method of delivery for retinal gene and stem-cell therapies, but its invasive and complex surgical procedure is a major limiting factor in clinical investigations and practice. Here, we engineered a novel trans-scleral injection technique to safely administer to the subretinal space in a simple, non-surgical, and minimally invasive procedure. Subretinal injection using this technique in rodents and rabbits took <1 min per injection and did not require a surgical microscope. Extensive safety examinations in rats showed that the injection technique reliably administered into the subretinal space with no incidence of retinal perforation, little or no choroidal bleeding, and no evidence of retinal toxicity. We further found that repeated subretinal injection in the same eye, in rats, was well tolerated. The developed technique may enable non-surgical subretinal injection without vitrectomy, potentially increasing safety, efficacy, and access to ocular therapies.

经巩膜微针注射视网膜下给药的非手术方法
治疗神经退行性眼病的新疗法已经出现,但受到非最佳眼部给药方法的限制。视网膜下注射是视网膜基因和干细胞治疗的首选方法,但其侵入性和复杂的手术过程是临床研究和实践的主要限制因素。在这里,我们设计了一种新的经巩膜注射技术,以一种简单、非手术和微创的方式安全地注射到视网膜下空间。在啮齿动物和兔子的视网膜下注射中使用这种技术每次注射需要1分钟,并且不需要手术显微镜。在大鼠中广泛的安全性检查表明,注射技术可靠地进入视网膜下间隙,没有发生视网膜穿孔,很少或没有脉络膜出血,也没有视网膜毒性的证据。我们进一步发现,在大鼠的同只眼睛中重复视网膜下注射具有良好的耐受性。该技术可以实现无需玻璃体切除的非手术性视网膜下注射,潜在地提高安全性、有效性和眼部治疗的可及性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信